Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The most frequently reported safety signals at the preferred term level associated with PARP inhibitors included Energy increased, Vitamin D decreased, Nocturia, Intentional underdose, Hunger, and Brain neoplasm.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Data on drug-related adverse events in ovarian cancer patients were sourced from the FAERS database between the third quarter of 2014 and the third quarter of 2025.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study

Study design awaiting verification · Frontiers in Pharmacology · 2026

Original publication title

Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study

Kui Yao; Hongling Peng

Copyright © 2026 Yao and Peng.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study systematically analyzed the safety signals related to different drugs during the treatment of ovarian cancer, which may assist clinicians in identifying drug alert signals.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The addition of targeted therapy and immunotherapy has significantly improved survival in ovarian cancer patients. This analysis aimed to investigate the adverse events associated with targeted and immunotherapy drugs in patients with ovarian cancer.

Source: Background

Abstract: What methods does the paper describe?

Adverse event reports related to bevacizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immune checkpoint inhibitors (ICI: PD-1, PD-L1, CTLA-4 inhibitors) in ovarian cancer were sourced from the FDA Adverse Event Reporting System (FAERS) database (Q3 2014 to Q3 2025). The disproportionality analysis, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN), was employed to detect safety signals associated with different drugs.

Source: Methods

Abstract: Results

A total of 209,920 adverse event reports were included in the analysis, involving 33,538 ovarian cancer patients. Among adverse events associated with the target drug (n = 183,935), 157,470 (85.61%) reports were related to PARP inhibitors, followed by bevacizumab [21,001 (11.42%)], PD-1 inhibitors [3,702 (2.01%)], PD-L1 inhibitors [1,317 (0.72%)], and CTLA-4 inhibitors [425 (0.23%)]. Adverse events are most frequently reported within 30 days of taking the medication. The most frequently reported safety signals at the preferred term level associated with PARP inhibitors included Energy increased, Vitamin D decreased, Nocturia, Intentional underdose, Hunger, and Brain neoplasm.

For bevacizumab, the most frequently reported safety signals were Gastrointestinal perforation, Proteinuria, Intestinal perforation, and Embolism. For ICI, the most frequently reported safety signals comprised Product use in unapproved indication, Off label use, Death, and Malignant neoplasm progression. The most frequently reported safety signals linked to combination therapy using different drugs vary. For the combination of bevacizumab and PARP inhibitors, the most frequently reported safety signals included Interstitial lung disease, Myelodysplastic syndrome, Myelosuppression, Acute myeloid leukaemia, and Proteinuria.

Source: Results

Abstract: Conclusion

This study systematically analyzed the safety signals related to different drugs during the treatment of ovarian cancer, which may assist clinicians in identifying drug alert signals.

Source: Conclusion
Authors’ abstract

Background

The addition of targeted therapy and immunotherapy has significantly improved survival in ovarian cancer patients. This analysis aimed to investigate the adverse events associated with targeted and immunotherapy drugs in patients with ovarian cancer.

Methods

Adverse event reports related to bevacizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immune checkpoint inhibitors (ICI: PD-1, PD-L1, CTLA-4 inhibitors) in ovarian cancer were sourced from the FDA Adverse Event Reporting System (FAERS) database (Q3 2014 to Q3 2025). The disproportionality analysis, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN), was employed to detect safety signals associated with different drugs.

Results

A total of 209,920 adverse event reports were included in the analysis, involving 33,538 ovarian cancer patients. Among adverse events associated with the target drug (n = 183,935), 157,470 (85.61%) reports were related to PARP inhibitors, followed by bevacizumab [21,001 (11.42%)], PD-1 inhibitors [3,702 (2.01%)], PD-L1 inhibitors [1,317 (0.72%)], and CTLA-4 inhibitors [425 (0.23%)]. Adverse events are most frequently reported within 30 days of taking the medication. The most frequently reported safety signals at the preferred term level associated with PARP inhibitors included Energy increased, Vitamin D decreased, Nocturia, Intentional underdose, Hunger, and Brain neoplasm.

For bevacizumab, the most frequently reported safety signals were Gastrointestinal perforation, Proteinuria, Intestinal perforation, and Embolism. For ICI, the most frequently reported safety signals comprised Product use in unapproved indication, Off label use, Death, and Malignant neoplasm progression. The most frequently reported safety signals linked to combination therapy using different drugs vary. For the combination of bevacizumab and PARP inhibitors, the most frequently reported safety signals included Interstitial lung disease, Myelodysplastic syndrome, Myelosuppression, Acute myeloid leukaemia, and Proteinuria.

Conclusion

This study systematically analyzed the safety signals related to different drugs during the treatment of ovarian cancer, which may assist clinicians in identifying drug alert signals.

Publication and source details

Original title: Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study

Kui Yao; Hongling Peng

Frontiers in Pharmacology · 2026

* Correspondence: Hongling Peng, penghongling12@163.com Copyright © 2026 Yao and Peng.2026Yao and Penghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:15:37.778753+00:00

DOI: 10.3389/fphar.2026.1867038 · PMC13337649